A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

卷:81

Article

Ortiz-Salvador, Jose-Maria¹  Saneleuterio-Temporal, Martina¹  Magdaleno-Tapial, Jorge¹  Velasco-Pastor, Manel²  Pujol-Marco, Conrad³  Sahuquillo-Torralba, Antonio³  Mateu-Puchades, Almudena⁴  Pitarch-Bort, Gerard⁵  Mari-Ruiz, Juan-Ignacio⁶  Matabi-Diaz, Javier⁷  Montesinos-Villaescusa, Encarna⁸  Miralles-Botella, Julia⁹  Garcia-Fernandez, Laura¹⁰  Martorell-Calatayud, Antonio¹¹  Belinchon-Romero, Isabel¹²  Sanchez-Carazo, Jose-Luis¹  Perez-Ferriols, Amparo¹ 

[1] Univ Gen Hosp Valencia, Dermatol Dept, Valencia, Spain

[2] Arnau de Vilanova Hosp Valencia, Dermatol Dept, Valencia, Spain

[3] La Fe Hosp Valencia, Dermatol Dept, Valencia, Spain

[4] Dr Peset Hosp Valencia, Dermatol Dept, Valencia, Spain

[5] Gen Hosp Castellon, Dermatol Dept, Castellon De La Plana, Spain

[6] La Ribera Univ, Dermatol Dept, Alzira, Spain

[7] Marina Baixa Hosp, Dermatol Dept, Alicante, Spain

[8] Valencia Clin Hosp, Dermatol Dept, Valencia, Spain

[9] San Juan Alicante Hosp, Dermatol Dept, Alicante, Spain

[10] Elda Hosp, Dermatol Dept, Elda, Spain

[11] Manises Hosp, Dermatol Dept, Manises, Spain

[12] Gen Hosp Alicante, Dermatol Dept, Alicante, Spain

关键词: biologic therapy;    IL-17;    psoriasis;    secukinumab;   

DOI  :  10.1016/j.jaad.2019.02.062

来源: Elsevier

【 摘 要 】

Background: Secukinumab is a first-in-class interleukin 17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in phase 3 studies. Objective: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiologic characteristics of patients treated with secukinumab in clinical settings. Methods: In this multicenter prospective observational study, we recruited adult patients with moderateto- severe plaque psoriasis from 12 hospitals in Spain during January-December 2016. These patients were treated with secukinumab and prospectively followed at 12-week intervals for 52 weeks. Results: In total, 158 patients were recruited to the study. A Psoriasis Area and Severity Index (PASI) score improvement $ 75% over baseline (PASI-75) was achieved by 57%, 83.5%, 89%, and 78.5% of patients at weeks 4, 12, 24, and 52, respectively. PASI-90 was achieved in 27.8%, 62%, 64.6%, and 63.2% of patients at weeks 4, 12, 24, and 52, respectively; PASI-75 and PASI-90 responders were significantly more common among patients with a body mass index < 30 kg/cm(2) and patients without previous biologic therapy failures. Limitations: Observational study. Time from onset of psoriasis was not evaluated. Conclusion: Secukinumab is a safe treatment with effectiveness rates similar to those found in its phase 3 studies. These rates endure up to a year from start of treatment.

【 授权许可】

Free